Literature DB >> 9151910

Clinicopathologic factors influencing the long-term prognosis following hepatic resection for large hepatocellular carcinoma more than 10 cm in diameter.

T Noguchi1, Y Kawarada, M Kitagawa, F Ito, H Sakurai, H Machishi, K Yamagiwa, H Yokoi, R Mizumoto.   

Abstract

We resected 158 cases of hepatocellular carcinoma (HCC), including 20 (12.6%) cases of large HCC. These 20 cases were divided into group 1 (curative resection, n = 9) and group 2 (noncurative resection, n = 11). The clinicopathologic features and long-term survival of the cases were evaluated. In groups 1 and 2, portal vein invasion (Vp+) was noted in 44.4% and 63.3%, intrahepatic metastasis (IM+) in 77.8% and 100%, absence of a fibrous capsule (Fc-) in 55.6% and 63.6%, and stage III or IV in 77.8% and 100%, respectively. The DNA ploidy pattern was aneuploid in 44.4% of group 1 and 100% of group 2. In group 1, the 1-, 3-, and 5-year cumulative survival rates were 75%, 62.5%, and 62.5%, respectively (the longest survivor is alive after 11 years 1 month). Five cases survived more than 3 years in group 1, and all were Vp(-) and nonaneuploid. On the other hand, in group 2, the 1-year survival rate was only 33.3%; none survived more than 2 years. These results suggest that even patients with large HCC have a favorable long-term prognosis if their clinicopathologic factors are Vp(-) and nonaneuploid, and if curative resection can be performed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151910

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

1.  Efficacy of hepatic resection for hepatocellular carcinomas larger than 10 cm.

Authors:  Yasuhiko Nagano; Kuniya Tanaka; Shinji Togo; Kenichi Matsuo; Chikara Kunisaki; Mitsutaka Sugita; Daisuke Morioka; Yasuhiko Miura; Toru Kubota; Itaru Endo; Hitoshi Sekido; Hiroshi Shimada
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

2.  Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.

Authors:  Jean-Nicolas Vauthey; Elijah Dixon; Eddie K Abdalla; W Scott Helton; Timothy M Pawlik; Bachir Taouli; Antoine Brouquet; Reid B Adams
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 3.  Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives.

Authors:  Gyu Sang Yoo; Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 4.  Localized hepatocellular carcinoma: therapeutic options.

Authors:  A Ribeiro; D M Nagorney; G J Gores
Journal:  Curr Gastroenterol Rep       Date:  2000-02

5.  Surgery for large primary liver cancer more than 10 cm in diameter.

Authors:  Xin-Da Zhou; Zhao-You Tang; Zeng-Chen Ma; Zhi-Quan Wu; Jia Fan; Lun-Xiu Qin; Bo-Heng Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-30       Impact factor: 4.553

6.  New indication for reduction surgery in patients with advanced hepatocellular carcinoma with major vascular involvement.

Authors:  Naoto Gotohda; Taira Kinoshita; Masaru Konishi; Toshio Nakagohri; Shinichiro Takahashi; Junji Furuse; Hiroshi Ishii; Masahiro Yoshino
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

Review 7.  Safety and efficacy of partial hepatectomy for huge (≥10 cm) hepatocellular carcinoma: a systematic review.

Authors:  Yan-Ming Zhou; Bin Li; Dong-Hui Xu; Jia-Mei Yang
Journal:  Med Sci Monit       Date:  2011-02-25

8.  Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.

Authors:  Wei-Lun Tsai; Kwok-Hung Lai; Huei-Lung Liang; Ping-I Hsu; Hoi-Hung Chan; Wen-Chi Chen; Hsien-Chung Yu; Feng-Woei Tsay; Huay-Min Wang; Hung-Chih Tsai; Jin-Shiung Cheng
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

9.  Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma.

Authors:  Wei-Lun Tsai; Wei-Chi Sun; Wen-Chi Chen; Chia-Ling Chiang; Huey-Shyan Lin; Huei-Lung Liang; Jin-Shiung Cheng
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.